- Prevalence and patient characteristics associated with cardiovascular disease risk 1
- 2 factor screening in UK primary care for people with severe mental illness: An
- 3 electronic healthcare record study
- 4
- Authors: Launders N¹, Jackson CA², Hayes JF^{1,3}, John A⁴, Stewart R^{5,6}, Iveson MH⁷, Bramon E^{1,3}, 5
- 6 Guthrie B², Mercer SW², Osborn DPJ^{1,3}.
- 7
- 8 Affiliations
- 9 1. Division of Psychiatry, University College London, London, United Kingdom
- 10 2. Usher Institute, The University of Edinburgh, Edinburgh, United Kingdom
- 11 3. Camden and Islington NHS Foundation Trust, London, United Kingdom
- 4. Swansea University Medical School, Swansea University, Swansea, United Kingdom 12
- 13 5. Institute of Psychiatry, Psychology and Neuroscience, Kings College London, London, United 14 Kingdom
- 15 6. South London and Maudsley NHS Foundation Trust, London, UK
- 16 7. Division of Psychiatry, Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, 17 United Kingdom
- 18
- 19 Manuscript word count: 3,466
- 20 Abstract word count: 249
- 21
- Abstract 22
- Background: 23
- 24 People with severe mental illness (SMI) are at increased risk of cardiovascular disease (CVD), and
- 25 initiatives for CVD risk factor screening in the UK have not reduced disparities.
- Objectives: 26
- 27 To describe the annual screening prevalence for CVD risk factors in people with SMI from April 2000
- 28 to March 2018, and to identify factors associated with receiving no screening and regular screening.
- 29 Methods:
- 30 We identified adults with a diagnosis of SMI (schizophrenia, bipolar disorder or 'other psychosis')
- 31 from UK primary care records in Clinical Practice Research Datalink (CPRD). We calculated the annual NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

- 32 prevalence of screening for blood pressure, cholesterol, glucose, body mass index, alcohol
- 33 consumption and smoking status, using multinomial logistic regression to identify factors associated
- 34 with receiving no screening and complete screening.
- 35 Results:
- 36 Of 216,136 patients with SMI, 55% received screening for all six CVD risk factors at least once follow-
- 37 up and 35% received all six within a one-month period. Changes in screening prevalence coincided
- 38 with changes in incentivisation of screening. In 2014-2018, men, people with a diagnosis of 'other
- 39 psychoses', or with missing ethnicity were more likely to have received no screening.
- 40 Conclusions:
- 41 The low proportion of people with SMI receiving regular comprehensive CVD risk factor screening is
- 42 concerning. Screening needs to be embedded as part of broad physical health checks to ensure the
- 43 health needs of people with SMI are being met. If we are to improve cardiovascular health,
- 44 interventions are needed where risk of receiving no screening or not receiving regular screening is
- 45 highest.

46 What is already known on this topic

- The prevalence of CVD risk factor screening in primary care increased with the introduction
 of an incentivisation scheme and when incentivisation for screening for specific CVD risk
- 49 factors is removed the screening decreases.

50 What does this study add?

Few patients received regular screening for all six CVD risk factors considered, and both
 screening prevalence and risk of receiving no screening varied depending on patient
 characteristics.

Only 35% of patients ever received screening for all six CVD risk factors considered in a one month period, suggesting that screening is not often being done as part of a physical health
 check.

57 How this study might affect research, practice or policy

- Clinicians should be aware that some sub-groups of patients with SMI are less likely to
- 59 receive screening, and the importance of providing screening as part of a regular,
- 60 comprehensive physical health check.

61 Background

People with severe mental illnesses (SMI), such as schizophrenia, bipolar disorder or other psychotic illnesses, are at increased risk of many physical health conditions¹². People with SMI have 1.5 to 2.5 times the risk of cardiovascular disease (CVD) compared to the general population and an increased risk of death from CVD³⁻⁷. They also have a higher prevalence of CVD risk factors, such as smoking, obesity and diabetes¹⁸⁻¹⁰, which is compounded by cardiometabolic side effects of antipsychotic medication¹¹, and sociodemographic risk factors^{12 13}.

68 In recognition of physical health disparities in people with SMI, financial incentivisation of physical 69 health checks for people with SMI in primary care was introduced in the UK in 2004 through the Qualities and Outcomes Framework (QOF)¹⁴. QOF initially incentivised a review of physical health, 70 71 with incentivisation of screening for individual CVD risk factors introduced in 2011. While blood 72 pressure and alcohol consumption screening have been consistently incentivised since 2011 and 73 smoking status has been incentivised since 2008, cholesterol, glucose and BMI screening have been 74 less consistently incentivised (see Table S1 for QOF changes related to SMI). Additionally, from 2014 the measures incentivised differed across the constituent countries of the UK, and Scotland and 75 Wales abolished QOF in 2016 and 2019 respectively. 76

77 Several studies have shown an increase in recording of CVD risk factors following the introduction of 78 QOF in people with SMI¹⁵⁻¹⁸, and a recent cohort study found that in England, removal of cholesterol 79 and BMI as incentivised indicators resulted in a decrease in recording of these risk factors compared to blood pressure recording¹⁹. However, there is a lack of evidence regarding long term trends in 80 81 screening prevalence for the six CVD risk factors currently included in the NHS England Physical 82 Health Check for SMI, and patient characteristics associated with receiving screening. In order to identify unmet need and improve the health of people with SMI, it is important to understand 83 84 whether incentivisation drives increases in screening in all patients with SMI, and to identify which 85 individuals may be at risk of not being screened. 86 Objective: To investigate the long-term trends and patient characteristics associated with receipt of 87 comprehensive CVD risk factor screening: blood pressure, cholesterol, glucose screening, BMI 88 measurement, alcohol consumption and smoking status.

89 Methods

90 Study design

- 91 We used Clinical Practice Research Datalink (CPRD) GOLD and Aurum databases to patients with SMI.
- 92 These databases contain deidentified healthcare records for patients registered with primary care
- 93 practices in the UK and are broadly representative of the UK population²⁰²¹. Our protocol was pre-
- 94 registered (<u>https://osf.io/czetb/</u>). We investigated annual screening prevalence of six CVD risk factors
- 95 at the population level. We then investigated screening patterns at an individual level and patient
- 96 characteristics associated with receipt of screening.

97 Population

- 98 We identified patients aged over 18 with a diagnosis of SMI (defined as schizophrenia, bipolar
- 99 disorder or other non-organic psychosis) recorded in primary care records. Entry to the cohort was
- 100 the latest of SMI diagnosis date, registration at primary care practice, or 1 April 2000. Exit was the

101 earliest of death, leaving the primary care practice, 100th birthday, or 31 March 2018. Patients did

102 not re-enter the cohort following exit.

103 Patients were required to have at least one year of follow-up following entry into the cohort to allow

- 104 time for screening to be recorded. In line with QOF reporting rules patients had to be registered with
- their primary care practice for the last three months of a financial year in order to be eligible for
- screening in that year. In the analysis of factors associated with CVD risk factor screening, we
- stratified the follow-up time into three periods; April 2004- March 2011; April 2011 March 2014;
- 108 April 2014 March 2018, based on major changes to the QOF incentivisation programme (Table S1).
- 109 Patients were included in each period if they were eligible for screening for at least two financial
- 110 years of that period.

111 Covariates

- 112 We defined the following covariates *a priori*:
- 113 We defined sex, primary care practice and country of primary care practice as recorded in CPRD, and
- 114 prescription of antipsychotics or mood stabilisers (lithium, sodium valproate or lamotrigine) based on
- 115 recorded prescriptions issued in primary care.
- 116 We defined age as under 40 years or 40 years and older based on year of birth, chosen because
- 117 cholesterol and blood glucose screening incentivisation was limited to those 40 years and over²². In
- 118 multinomial logistic regression models, we included age at start of follow-up as a continuous variable
- and reported effect size as odds ratios (OR) per 10-year increase in age.
- 120 We defined ethnicity as recorded in primary care records and grouped as per the UK 2011 Census²³.
- 121 We defined specific SMI diagnosis was defined as the most recently recorded of schizophrenia,
- 122 bipolar disorder or other non-organic psychotic illness.
- 123 We defined presence on other QOF registers which incentivise CVD risk factor screening as having a
- 124 Read code used in the 2017-2018 QOF incentivisation for any of: atrial fibrillation, coronary heart

disease, hypertension, peripheral artery disease, stroke or diabetes. Exception reporting was defined
as ever having a Read code that would remove a patient from the incentivisation denominator for
the mental health domain (i.e. deemed unsuitable, withdrew consent, or didn't respond to

128 invitations for screening).

129 Outcomes

- 130 We investigated screening of six individual CVD risk factors (cholesterol, blood glucose, blood
- 131 pressure, BMI, smoking status and alcohol consumption screening), and a composite outcome of all
- 132 six. For glucose, we included codes for blood glucose or HbA1C tests or values, but excluded urine
- 133 testing. For cholesterol, we included any screening code or value. For blood pressure, we included
- 134 screening codes or values for either diastolic or systolic blood pressure. For BMI we included BMI
- values, BMI calculated from height and weight, and screening codes. For smoking and alcohol status
- 136 we included any screening code. Further details on the prevalence of CVD risk factors in this cohort is
- 137 available on the DATAMIND website (https://datamind.org.uk/data/harmonised-data/smi-cohorts/)
- and code lists used to define the population, covariates and outcomes are available in the HDR UK
- 139 phenotype library (Table S2).
- 140 In the individual-level analysis of factors associated with CVD risk factor screening, in each time
- 141 period a patient was considered to have 'always complete screening' if they received screening for all
- six CVD risk in each financial year in the time period that they were active. Irregular screening was
- 143 defined as any frequency between 'always complete screening' and receiving no screening.

144 Statistical analysis

145 We calculated the annual prevalence of recorded screening of each of the six CVD risk factors,

stratifying by the aforementioned covariates. We calculated the proportion of patients receiving all

- six CVD risk factors ever during follow-up, ever within a one-month period, and for each financial
- 148 year.

149 We conducted multinomial logistic regression analyses to assess patient factors associated with

- 150 receiving 'always complete' CVD risk factor screening and receiving no screening in each of the three
- 151 time periods, compared to receiving irregular screening.
- 152 We mutually adjusted for all covariates in the models, with the exception of primary care practice
- 153 which was used as a clustering term in the calculation of sandwich standard errors. We additionally
- adjusted for the time since SMI diagnosis, time since primary care practice registration, year of end
- 155 of follow-up and total follow-up time. Analysis was performed in R and R Studio and reported in line
- 156 with the RECORD checklist²⁴.

157 Missing data

- 158 Missing ethnicity was included as a separate category as those with missing ethnicity are different to
- those with a recorded ethnicity with respect to healthcare access and engagement. For all diagnostic
- 160 and screening variables, we deemed absence of a code to indicate an absence of diagnosis or
- 161 screening. We excluded 122 patients who were missing geographical data from the analysis.

162 Sensitivity analyses

- 163 In *a priori* sensitivity analysis we limited the population to patients resident in England with available
- 164 deprivation data (English Index of Multiple Deprivation (IMD) quintiles). In post-hoc analysis we
- 165 limited the model to patients who were active for the whole of the follow-up period due to the
- 166 strong effect of follow-up time on the completeness of screening.

167 PPI involvement

- 168 Lived experience advisors from the DATAMIND Super Research Advisory Group
- 169 (https://datamind.org.uk/patients-and-public/the-super-research-advisory-group/) and UCL Mental
- 170 Health Data Science PPIE group commented on the protocol and provided input into the
- 171 interpretation of results.

172 Findings

- 173 We identified 312,471 patients with a diagnostic code for SMI at any time, of whom 216,136 had a
- diagnosis of SMI before the end of follow-up, were over the age of 18 years, with at least one year of
- 175 registration and without missing geographic data (Figure S1). Patients had a median of 4.85 (IQR:
- 176 2.43, 9.72) years of follow-up (Table 1).
- 177 Table 1: Characteristics of the cohort of patients with severe mental illness in CPRD, n=216,136


Characteristic		n (%) / median [IQR]
Age at SMI diagnosi	s (median [IOR])	
		35 [26, 48]
-	w-up (median [IQR])	44 [33, 59]
Age at end of follow		52 [39, 68]
Follow-up time ^a (me	edian [IQR])	4.85 [2.43, 9.72]
Sex, n (%)	Male	111,655 (51.7)
	Female	104,481 (48.3)
Ethnicity, n (%)	Asian	7,679 (3.6)
	Black	9,979 (4.6)
	Mixed	2,733 (1.3)
	Other	4,199 (1.9)
	White	110,673 (51.2)
	Missing	80,873 (37.4)
Country, n (%)	England	186,880 (86.5)
	Northern Ireland	3,405 (1.6)
	Scotland	14,010 (6.5)
	Wales	11,841 (5.5)
Most recent SMI		
diagnosis, n (%)	Schizophrenia	73,753 (34.1)
	Bipolar disorder	68,921 (31.9)
	Other psychoses	73,462 (34.0)
Ever exception repo	orted, n (%)	59,736 (27.6)
Ever on another CVI	D QOF register ^b , n (%)	64,295 (29.8)
Ever prescribed anti n (%)	psychotics, lithium, sodium valproate or lamotrigine,	173,669 (80.3)
Died during follow-	up ^a , n (%)	31,210 (14.4)
Age at death (media	an [IQR])	75.49 [62.44, 84.74]


SMI: Severe Mental Illness; CVD: cardiovascular disease; IQR: interquartile range; QOF: Quality and Outcomes
 Framework

a: Follow-up starts at the latest of 01/04/2000, primary care practice registration, SMI diagnosis or age 18 and
ends at the earliest of death, leaving the primary care practice, age 100 or last data collection by CPRD.

b: Defined as presence on QOF register for atrial fibrillation, coronary heart disease, hypertension, peripheral
 artery disease, stroke or diabetes.

- 185 Population-level analysis of cardiovascular disease risk factor screening
- 186 The prevalence of smoking and blood pressure screening increased steadily during the study period.
- 187 In contrast, for alcohol, BMI, cholesterol and glucose screening the prevalence of screening increased
- 188 sharply in 2011-2012 following the introduction of incentivisation of individual CVD risk factors. For
- 189 BMI, cholesterol and glucose screening the prevalence decreased rapidly from 2013-2014 to 2014-
- 190 2015, coinciding with the withdrawal of financial incentives (Figure 1, Table S3).
- Figure 1: Prevalence of cardiovascular risk factor screening in people with severe mental illness, in the
 primary care setting in the UK by financial year





alcohol, blood pressure and smoking were individually incentivised in England, while incentivisation differed in
 Northern Ireland, Scotland and Wales (2014-2015). BMI: Body mass index

198

- 199 These broad patterns remained when stratified by most patient characteristics (Figures S2-S10). 200 However, the increase in cholesterol and glucose screening in 2011-2013 was primarily observed in 201 those aged 40 years or older (Figure S2), the population incentivised at the time. While the 202 prevalence of screening increased for all countries from 2000 to 2014, from 2014 to 2018 (a period 203 of diverging incentivisation across the four nations) the pattern was less consistent (Figure S3). 204 Screening for all CVD risk factors was lowest in those with a diagnosis of 'other psychoses' (Figure 205 S4), men (Figure S5), those not on another QOF register (Figure S6) and those not on antipsychotics 206 or mood stabilisers (Figure S7). Screening prevalence for smoking was highest in patients of White or 207 Mixed ethnicity, and screening of other CVD risk factors was highest in patients of Asian ethnicity 208 (Figure S7). 209 Individual-level factors associated with receiving 'always complete' or no CVD risk factor 210 screening 211 Almost all patients (93.9%) received screening for at least one of the six CVD risk factors at some 212 point during follow-up. However, only half (54.8%) received screening for all six CVD risk factors at
- least once (Table 2), and this occurred within a one-month period at least once for only 34.8% of

214 patients.

Table 2: Proportion of patients with severe mental illness ever receiving screening for: each cardiovascular disease (CVD) risk factor; any of the six CVD risk factor; and of the six CVD risk factors, stratified by covariates, 2000-2018

		n	Cholesterol, n(%)	Glucose, n(%)	Blood pressure, n(%)	BMI, n(%)	Smoking, n(%)	Alcohol, n(%)	Any screening measure ever, n(%)	Ever received all 6 measures, n(%)
All		216,136	136,897 (63.3)	151,652 (70.2)	189,844 (87.8)	168,378 (77.9)	190,967 (88.4)	172,441 (79.8)	202,900 (93.9)	118,351 (54.8)
Age at start of	Under 40	85,094	42,548 (50.0)	49,781 (58.5)	70,464 (82.8)	65,073 (76.5)	75,353 (88.55)	67,778 (79.7)	78,660 (92.4)	37,467 (44.0)
follow-up	40+	131,042	94,349 (72.0)	101,871 (77.7)	119,380 (91.1)	103,305 (78.8)	115,614 (88.2)	104,663 (79.9)	124,240 (94.8)	80,884 (61.7)
Sex	Male	111,655	68,285 (61.2)	73,664 (66.0)	94,744 (84.6)	85,708 (76.8)	98,423 (88.1)	89,405 (80.1)	103,497 (92.7)	59,466 (53.3)
	Female	104,481	68,612 (65.7)	77,988 (74.6)	95,100 (91.0)	82,670 (79.1)	92,544 (88.6)	83,036 (79.5)	99,403 (95.1)	58,885 (56.4)
Ethnicity	Asian	7,679	5,896 (76.8)	6,234 (81.2)	7,192 (93.7)	6,886 (89.7)	7,317 (95.3)	7,079 (92.2)	7,533 (98.1)	5,457 (71.1)
	Black	9,979	6,966 (69.8)	7,386 (74.0)	9,189 (92.1)	8,684 (87.0)	9,410 (94.3)	8,933 (89.5)	9,697 (97.2)	6,366 (63.8)
	Mixed	2,733	1,755 (64.2)	1,885 (69.0)	2,472 (90.5)	2,344 (85.8)	2,610 (95.5)	2,455 (89.8)	2,677 (98.0)	1,575 (57.6)
	Other	4,199	2,652 (63.2)	2,969 (70.7)	3,710 (88.4)	3,264 (77.7)	3,860 (91.9)	3,382 (80.5)	4044 (96.3)	2,222 (52.9)
	White	110,673	80,734 (72.9)	86,716 (78.4)	103,788 (93.8)	97397 (88.0)	106,716 (96.4)	100,784 (91.1)	109,203 (98.7)	73,018 (66.0)
	Missing	80,873	38,894 (48.1)	46,462 (57.5)	63,493 (78.5)	49,803 (61.6)	61,054 (75.5)	49,808 (61.6)	69,740 (86.2)	29,677 (36.7)
Country	England	186,880	117,627 (62.9)	130,688 (69.9)	164,352 (87.9)	145,296 (77.7)	165,068 (88.3)	149,262 (79.9)	175,491 (93.9)	101,644(54.4)
	Northern Ireland	3,405	2,546 (74.8)	2,716 (79.8)	3,069 (90.1)	2,816 (82.7)	3,053 (89.7)	2,797 (82.1)	3,220 (94.6)	2,208 (64.8)
	Scotland	14,010	8,975 (64.1)	9,422 (67.3)	11,994 (85.6)	10,813 (77.2)	122,27 (87.3)	10,835 (77.3)	12,971 (92.6)	7,708 (55.0)
	Wales	11,841	7,749 (65.4)	8,826 (74.5)	10,429 (88.1)	9,453 (79.8)	10,619 (89.7)	9,547 (80.6)	11,218 (94.7)	6,791 (57.35)
SMI diagnosis	Schizophrenia	73,753	47,869 (64.9)	51,813 (70.3)	64,368 (87.3)	57,927 (78.5)	64,902 (88.0)	58,788 (79.7)	68,449 (92.8)	42,132 (57.1)
	Bipolar disorder	68,921	46,587 (67.6)	51,431 (74.6)	62,488 (90.7)	56,195 (81.5)	62,394 (90.5)	56,951 (82.6)	65,874 (95.6)	40,529 (58.8)
	Other psychoses	73,462	42,441 (57.7)	48,408 (65.9)	62,988 (85.7)	54,256 (73.9)	63,671 (86.7)	56,702 (77.2)	68,577 (93.4)	35,690 (48.6)
Ever exception reported	No	156,376	96,387 (61.6)	107,467 (68.7)	135,588 (86.7)	118,881 (76.0)	134,324 (85.9)	120,774 (77.2)	144,623 (92.5)	82,463 (52.73)
	Yes	59,760	40528 (67.8)	44203 (74.0)	54277 (90.8)	49,497 (82.8)	56667 (94.8)	51691 (86.5)	58,277 (97.5)	35,888 (60.05)
Ever other	No	151,841	81,417 (53.6)	94,124 (62.0)	127,397 (83.9)	113,031 (74.4)	131,518 (86.6)	117,208 (77.2)	139,715 (92.0)	69,972 (46.08)
QOF ^a	Yes	64,295	55,480 (86.3)	57,528 (89.5)	62,447 (97.1)	55,347 (86.1)	59,449 (92.5)	55,233 (85.9)	63,185 (98.2)	48,379 (75.2)

prescribed antipsychotics /mood Yes 173,669 117,719 (67.8) 129,581 (74.6) 156,816 (90.3) 156,305 (90.0) 142,501 (82.1)			n	Cholesterol, n(%)	Glucose, n(%)	Blood pressure, n(%)	BMI, n(%)	Smoking, n(%)	Alcohol, n(%)	Any screening measure ever, n(%)	Ever received all 6 measures, n(%)
prescribed antipsychotics /mood Yes 173,669 117,719 (67.8) 129,581 (74.6) 156,816 (90.3) 156,305 (90.0) 142,501 (82.1)	Ever	No	42,467	19,178 (45.2)	22,071 (52.0)	33,028 (77.8)	28,426 (66.9)	34,662 (81.6)	29,940 (70.5)	37,439 (88.2)	15,399 (36.3)
stabilizers 130 052 (80 6) 165 461 (05 3) 102 052	antipsychotics	Yes	173,669	117,719 (67.8)	129,581 (74.6)	156,816 (90.3)	139,952 (80.6)	156,305 (90.0)	142,501 (82.1)	165,461 (95.3)	102,952 (59.3)

217 SMI: Severe Mental Illness; BMI: Body mass index; QOF: Quality and Outcomes Framework

218 a: Defined as presence on QOF register for atrial fibrillation, coronary heart disease, hypertension, peripheral artery disease, stroke or diabetes.

219 In the period prior to all six CVD risk factors being incentivised (2004-2011) 1.7% of patients received 220 'always complete' screening (i.e. all six CVD risk factors each financial year that they were active 221 between 2004 and 2011). This increased to 14.8% during the period of individual incentivisation 222 (2011-2014) and decreased to 8.3% following that (2014-2018; Table 3). 223 The odds of receiving no screening in the 2014-2018 and 2011-2014 periods were higher for men, 224 patients of 'other' or missing ethnicity (compared to White ethnicity) and those who had been 225 exception reported from QOF, even after mutual adjustment for covariates (Tables 3 & 4). Conversely, 226 those on other QOF registers which incentivise screening or who had been prescribed antipsychotics 227 or mood stabilisers were less likely to receive no screening in each time period (Tables 3 & 4). In 228 adjusted analyses, compared to patients in England, patients resident in Scotland or Wales were less 229 likely to receive no screening in the 2011-2014 period, but more likely to receive no screening in the 230 2014-2018 period when both countries reduced incentives in varying ways (Table 4, Table S1). 231 In the 2014-2018 period only, older age was associated with lower odds of receiving no screening (OR per 10-year increase in age: 0.86; 95%CI:0.83-0.90), and compared to bipolar disorder, a 232 233 diagnosis of 'other psychoses' was associated with higher odds of receiving no screening (Table 4). In 234 the 2011-2014 period only, compared to White ethnicity, Black ethnicity was associated with higher 235 odds of receiving no screening (OR:1.31; 95%CI:1.03-1.67).

Table 3: Unadjusted multinomial logistic regression for the odds ratio of always receiving complete screening^a or receiving no screening compared to

238 *irregular screening, among people with severe mental illness, during two time periods*

		April 2011 – March 20)14 (n=85,274)	April 2014 – March 2018 (n=94,216)		
Reference: Irregular scre	ening	Complete (n=12,616, 14.79%)	None (n=3,204, 3.76%)	Complete (n=7,771, 8.25%)	None (n=2,092, 2.22%)	
		OR (95% CI)	OR (95% CI)	OR (95% CI)	OR (95% CI)	
Age at start of follow-up	Per 10-year increase	1.26 (1.24-1.27)	1.00 (0.95-1.06)	1.27 (1.24-1.28)	0.82 (0.79-0.94)	
Sex (ref female)	Male	1.03 (0.98-1.07)	1.58 (1.46-1.72)	1.09 (1.04-1.15)	1.93 (1.75-2.12)	
	Asian	1.13 (1.00-1.28)	1.02 (0.81-1.30)	1.54 (1.34-1.78)	0.82 (0.62-1.09)	
	Black	0.81 (0.71-0.92)	1.60 (1.27-2.02)	1.18 (1.01-1.37)	1.35 (1.08-1.68)	
Ethnicity (ref White)	Mixed	0.65 (0.53-0.78)	1.24 (0.85-1.80)	0.83 (0.67-1.01)	0.89 (0.58-1.36)	
	Other	0.68 (0.57-0.81)	2.43 (1.88-3.13)	0.73 (0.58-0.93)	2.12 (1.61-2.79)	
	Missing	0.73 (0.66-0.80)	4.76 (3.92-5.78)	0.68 (0.61-0.75)	2.62 (2.33-2.95)	
	Northern Ireland	1.04 (0.69-1.57)	0.55 (0.37-0.79)	0.58 (0.35-0.94)	1.31 (0.90-1.90)	
Country (ref England)	Scotland	1.36 (1.17-1.59)	0.85 (0.68-1.07)	1.06 (0.86-1.30)	3.02 (2.59-3.52)	
	Wales	0.66 (0.55-0.79)	0.80 (0.61-1.58)	0.52 (0.43-0.65)	1.95 (1.57-2.42)	
SMI diagnosis (ref bipolar disorder)	Schizophrenia	1.26 (1.20-1.32)	1.31 (1.19-1.45)	1.38 (1.30-1.48)	1.17 (1.04-1.32)	
	Other psychoses	0.83 (0.78-0.87)	1.44 (1.27-1.63)	0.87 (0.82-0.93)	1.82 (1.63-2.03)	
In period variables ^d	Exception reported ^b	0.37 (0.35-0.39)	1.46 (1.19-1.80)	0.45 (0.42-0.48)	2.14 (1.92-2.38)	
	Other QOF register ^c	2.30 (2.17-2.42)	0.28 (0.25-0.31)	3.71 (3.39-4.07)	0.28 (0.52-0.30)	
	On antipsychotics/mood stabilisers	2.05 (1.93-2.18)	0.14 (0.13-0.16)	2.14 (1.97-2.32)	0.21 (0.19-0.23)	
	Years since diagnosis	1.00 (1.00-1.00)	1.00 (1.00-1.00)	1.00 (1.00-1.00)	1.00 (1.00-1.00)	
	Years since registration	1.00 (1.00-1.00)	1.00 (1.00-1.00)	1.00 (1.00-1.00)	1.00 (1.00-1.00)	
	Years of follow-up	1.00 (1.00-1.00)	0.998 (0.998-0.999)	1.00 (1.00-1.00)	0.999 (0.999-1.0	
Year of end of record in	Year 2	0.00 (00.00-0.00)	0.00 (00.00-0.00)	0.43 (0.57-3.15)	5.07 (1.52-16.87	
period (ref final year) ^e	Year 3	NA	NA	1.66 (1.51-1.83)	2.50 (2.19-2.86)	

239 OR: Odds ratio; 95% CI: 95% confidence interval; ref: Reference category; SMI: Severe Mental Illness; QOF: Quality and Outcomes Framework

240 a: Complete screening was defined as screening of all six cardiovascular risk factors for each year that the patient is active

b: Exception reported from mental health measures

- 242 c: Defined as presence on QOF register for atrial fibrillation, coronary heart disease, hypertension, peripheral artery disease, stroke or diabetes.
- 243 d: In period variables measured cross-sectionally, up to the end of the period of interest
- e: Defined as the year a patient ends follow-up. For the 2014-2018 cohort, year two is 2015-2016, year 3 is 2016-2017 and the final year is 2017-2018. For the 2011-2014
- cohort year 2 is 2012-2013 and the final year is 2013-2014.
- 246 Note: Patients could be present in both time periods. The total number of unique patients is 119,976

247	Men were both more likely to have received no screening, and to have always received complete
248	screening than women in both time periods. Men, older patients, those of Asian ethnicity (compared
249	to those of White ethnicity), with a diagnosis of schizophrenia (compared to bipolar disorder),
250	prescribed antipsychotics or mood stabilisers, on a QOF register that incentivised CVD risk factor, and
251	who were never exception reported were more likely to always receive complete screening in all time
252	periods, in unadjusted and adjusted models (Table 3 & 4 and Table S4). Patients of Black (versus
253	White) ethnicity were more likely to always have complete screening in the 2014-2018 period only
254	(OR:1.39; 95%CI:1.19-1.62, Table 4).
255	Characteristics associated with receipt of screening differed for individual CVD risk factors. For
256	example, in the 2014-2018 period men were more likely to have received regular glucose, cholesterol
257	or smoking screening, but women were more likely to have received regular blood pressure
258	screening. Patients of Black ethnicity were less likely to have received no screening for glucose,
259	cholesterol, and BMI, had similar odds of alcohol and blood pressure screening but were more likely
260	to have received no smoking screening than patients of White ethnicity (Table S5).
261 262	Sensitivity analysis: Investigating the effect of deprivation and follow-up time Limiting the population to those with available deprivation data or those with complete follow-up for
263	each period did not alter most findings (Table S6-S7). Deprivation was not associated with receiving
264	always complete or no screening, except for in the 2014-2018 period, where those in the most
265	deprived quintile were less likely to have received no screening than those in the least deprived

266 quintile (OR:0.74; 95%CI:0.56-0.99, Table S6).

267 Table 4: Adjusted multinomial logistic regression^a for the odds ratio of always receiving complete screening^a or receiving no screening compared to irregular

268 screening, among people with severe mental illness, during two time periods

		April 2011 – March 2014 (n=85,274)		April 2014 – March 2018 (n=94,216)		
Reference: Irregular screening		Complete (n=12,616, 14.79%)	None (n=3,204, 3.76%)	Complete (n=7,771, 8.25%)	None (n=2,092, 2.22%)	
Age at start of follow-up	Per 10-year increase	1.18 (1.17-1.21)	1.01 (0.96-1.05)	1.15 (1.14-1.17)	0.86 (0.83-0.90)	
Sex (ref female)	Male	1.24 (1.19-1.30)	1.31 (1.21-1.43)	1.33 (1.26-1.41)	1.41 (1.27-1.56)	
Ethnicity (ref White)	Asian	1.24 (1.09-1.41)	1.00 (0.78-1.29)	1.75 (1.51-2.04)	0.88 (0.66-1.17)	
	Black	0.93 (0.82-1.06)	1.31 (1.03-1.67)	1.39 (1.19-1.62)	1.23 (0.98-1.55)	
	Mixed	0.81 (0.67-0.97)	1.02 (0.69-1.50)	1.04 (0.85-1.28)	0.83 (0.54-1.28)	
	Other	0.77 (0.65-0.92)	2.56 (1.98-3.31)	0.83 (0.67-1.03)	1.66 (1.29-2.15)	
	Missing	0.69 (0.63-0.76)	5.26 (4.34-6.38)	0.70 (0.63-0.78)	2.15 (1.89-2.44)	
Country (ref England)	Northern Ireland	1.14 (0.75-1.73)	0.33 (0.22-0.48)	0.60 (0.38-0.97)	1.17 (0.78-1.74)	
	Scotland	1.56 (1.32-1.86)	0.67 (0.53-0.84)	1.15 (0.93-1.44)	2.88 (2.43-3.41)	
	Wales	0.81 (0.67-0.97)	0.48 (0.36-0.64)	0.65 (0.54-0.79)	1.51 (1.21-1.88)	
SMI diagnosis (ref bipolar	Schizophrenia	1.27 (1.20-1.34)	0.99 (0.89-1.10)	1.30 (1.22-1.39)	0.90 (0.79-1.03)	
disorder)	Other psychoses	0.92 (0.88-0.97)	1.05 (0.94-1.17)	0.96 (0.90-1.02)	1.22 (1.09-1.37)	
In period variables ^d	Exception reported ^b	0.38 (0.36-0.41)	1.26 (1.08-1.47)	0.47 (0.44-0.51)	1.69 (1.51-1.89)	
	Other QOF register ^c	1.93 (1.82-2.04)	0.31 (0.28-0.35)	3.21 (2.93-3.53)	0.35 (0.31-0.39)	
	On antipsychotics/mood stabilisers	1.89 (1.77-2.01)	0.17 (0.15-0.19)	1.95 (1.80-2.11)	0.24 (0.21-0.26)	
	Years since diagnosis	1.00 (1.00-1.00)	1.00 (1.00-1.00)	1.00 (1.00-1.00)	1.00 (1.00-1.00)	
	Years since registration	1.00 (1.00-1.00)	1.00 (1.00-1.00)	1.00 (1.00-1.00)	1.00 (1.00-1.00)	
	Years of follow-up	1.00 (1.00-1.00)	1.00 (1.00-1.00)	1.00 (1.00-1.00)	1.00 (1.00-1.00)	
Year of end of record in	Year 2	0.00 (00.00-0.00)	0.00 (00.00-0.00)	0.28 (0.04-2.14)	4.67 (1.05-20.71)	
period (ref final year) ^e	Year 3	NA	NA	1.35 (1.21-1.50)	2.47 (2.10-2.90)	

269 OR: Odds ratio; 95% CI: 95% confidence interval; ref: Reference category; SMI: Severe Mental Illness; QOF: Quality and Outcomes Framework

270 a: Multinomial logistic regression comparing patients receiving no screening or receiving complete screening (all six cardiovascular risk factors for each year that the patient

is active in the time period) to those who were irregularly screened, with mutual adjustment for all covariates.

b: Exception reported from mental health measures

273 c: Defined as presence on QOF register for atrial fibrillation, coronary heart disease, hypertension, peripheral artery disease, stroke or diabetes.

- d: In period variables measured cross-sectionally, up to the end of the period of interest
- e: Defined as the year a patient ends follow-up. For the 2014-2018 cohort, year two is 2015-2016, year 3 is 2016-2017 and the final year is 2017-2018. For the 2011-2014
- cohort year 2 is 2012-2013 and the final year is 2013-2014.
- 277 Note: Patients could be present in both time periods. The total number of unique patients is 119,976

278 Discussion

279	We found that cardiovascular risk factor screening prevalence varied by individual CVD risk factor,
280	over time, and by patient characteristics. Our findings suggest that patient characteristics and
281	financial incentivisation influence screening prevalence of individual CVD risk factors, the likelihood
282	of receiving screening for all six CVD risk factors annually, and risk of receiving no screening.
283	However, as the patient characteristics associated with increased risk of receiving no screening
284	change over the study periods, it is likely that the groups most at risk of missing screening are
285	dynamic and dependent on which measures are incentivised. Between 2014 and 2018, men, younger
286	patients and those without pre-existing conditions, not prescribed antipsychotics or mood stabilisers,
287	of missing or 'other' ethnicity, or with a diagnosis of 'other psychoses' had an elevated risk of
288	receiving no screening.
289	We found a sharp increase in CVD risk factor screening in 2011, most notable for alcohol, BMI,
289 290	We found a sharp increase in CVD risk factor screening in 2011, most notable for alcohol, BMI, cholesterol and glucose screening, and coinciding with the introduction of incentivisation of all six of
290	cholesterol and glucose screening, and coinciding with the introduction of incentivisation of all six of
290 291	cholesterol and glucose screening, and coinciding with the introduction of incentivisation of all six of the CVD risk factors studied. The subsequent reduction in prevalence of glucose, cholesterol and BMI
290 291 292	cholesterol and glucose screening, and coinciding with the introduction of incentivisation of all six of the CVD risk factors studied. The subsequent reduction in prevalence of glucose, cholesterol and BMI screening in 2014 coincides with the removal of these measures from incentivisation in England and
290 291 292 293	cholesterol and glucose screening, and coinciding with the introduction of incentivisation of all six of the CVD risk factors studied. The subsequent reduction in prevalence of glucose, cholesterol and BMI screening in 2014 coincides with the removal of these measures from incentivisation in England and Northern Ireland, a pattern not seen in the screening prevalence of CVD risk factors which remained
290 291 292 293 294	cholesterol and glucose screening, and coinciding with the introduction of incentivisation of all six of the CVD risk factors studied. The subsequent reduction in prevalence of glucose, cholesterol and BMI screening in 2014 coincides with the removal of these measures from incentivisation in England and Northern Ireland, a pattern not seen in the screening prevalence of CVD risk factors which remained incentivised in these countries ²² . This is in line with a recent study by Matias et al, which found a
290 291 292 293 294 295	cholesterol and glucose screening, and coinciding with the introduction of incentivisation of all six of the CVD risk factors studied. The subsequent reduction in prevalence of glucose, cholesterol and BMI screening in 2014 coincides with the removal of these measures from incentivisation in England and Northern Ireland, a pattern not seen in the screening prevalence of CVD risk factors which remained incentivised in these countries ²² . This is in line with a recent study by Matias et al, which found a significant reduction in screening for cholesterol and BMI in this period compared to blood pressure

298 Strengths and limitations

The large population size allowed us to stratify results by a range of patient characteristics, while the representative nature of CPRD data makes these results generalisable to the UK for this time period, although with notable differences across the four nations of the UK from 2014. Focusing on longitudinal screening at an individual level, as well as screening prevalence at a population level

allowed a better understanding of screening practice over time and the identification of groups of
 patients who are at risk of receiving no screening. Our results highlight the importance of considering
 regularity and comprehensiveness of screening at an individual level when evaluating screening
 interventions, rather than reliance on prevalence of screening at a population level.

307 We required that patients had at least one year of during the study period to reliably capture 308 screening activity. This may mean that patients who are transiently registered, who are less likely to 309 be screened, are not included in our results. Our analysis was exploratory in nature and while we 310 investigated a range of factors that we hypothesised were associated with receipt of CVD risk factor 311 screening in primary care, it is likely that many of these factors interact to produce distinct risk 312 profiles. Furthermore, we did not investigate outcomes of screening practices and therefore cannot 313 determine the impact that screening has on for example stopping smoking, having controlled blood 314 pressure or starting statins, nor on the longer-term health of people with SMI. There is a need for 315 further hypothesis-driven studies to identify groups of patients at risk of missed screening, the impact this has on cardiovascular health and into the effectiveness of physical health checks and CVD 316 317 risk factor screening in this population.

318 Clinical Implications

Given the known cardiovascular health inequalities in those with SMI³⁻⁷, the finding that only half of 319 320 patients with SMI had ever received screening for all six CVD risk factors is concerning. Our results 321 suggests that while incentivisation led to an increase in the annual prevalence of screening for 322 individual CVD risk factors, few patients received regular comprehensive screening. In 2023, the 323 proportion of patients with SMI receiving screening for all six CVD risk factors was incentivised for 324 the first time^{26 27}. While data collected by NHS England for physical health checks performed in primary or secondary care suggests this has increased the prevalence of screening, ²⁸our study 325 326 highlights the need to consider regularity of screening as well as differences in screening prevalence, 327 the risk of receiving no screening and always receiving complete screening by patient characteristics. We found a low prevalence of screening, and high risk of receiving no screening in those with missing ethnicity, without pre-existing conditions or of younger age. While for those with missing ethnicity, this is likely driven by lack of healthcare contact underpinning both poor ethnicity recording and low levels of screening, for those of younger age or without other physical health conditions it may be driven by additional factors, such as patient and provider perceptions of need. Further interventions are therefore required to improve uptake in these groups.

334 Incentivisation appears to confer little benefit to those outside of the incentivisation criteria. For 335 example, we found that when cholesterol and glucose screening was incentivised for patients with 336 SMI aged over 40, there was minimal increase in screening in those under 40, so little evidence of 337 halo effects. Likewise, those with 'other psychoses' had a lower screening prevalence of all CVD risk 338 factors than patients with schizophrenia or bipolar disorder. The term 'other psychoses' covers a 339 range of psychotic diagnoses and symptoms, and is broader than the list included under QOF 340 incentivisation. These findings highlight the careful planning needed when implementing incentivisation so that those falling outside of incentivisation but still at risk are not marginalised, 341 342 particularly in those with SMI, who may develop multimorbidity at an early age¹, and where formal 343 diagnosis may be delayed.

344 People with SMI are at risk of physical health conditions beyond CVD¹, and of avoidable physical 345 health hospitalisations²⁹. Current NHS guidance describes the incentivised CVD risk factors as core to 346 the physical health check in primary care, but recommends a more comprehensive annual review of physical health³⁰. We found that only a third of patients ever received screening of all six CVD risk 347 factors within a month of each other suggesting that CVD risk factors may be captured 348 349 opportunistically. While opportunistic screening results in higher screening prevalence, screening is 350 only a first step. It is important that patients also receive a comprehensive clinical review of physical 351 health so that coordinated actions can be put in place to manage CVD risk, and diagnose and treat 352 conditions beyond CVD. While physical health screening is embedded in primary care, further

- 353 consideration is warranted as to the provision of physical health checks in mental health services to
- 354 complement those in primary care and to provide services to those not regularly in contact with their
- 355 primary care provider. However, this approach is reliant on improved coordination between physical
- and mental health care providers to avoid duplication for both patient and practitioner, and to
- 357 ensure transfer of important patient information.

358 Conclusions

- 359 The low proportion of people receiving regular CVD risk factor screening suggests that people with
- 360 SMI are not reliably receiving regular comprehensive physical health checks in primary care. Further
- 361 consideration is warranted as to how incentivisation and other schemes could improve the regularity
- 362 and comprehensiveness of screening, rather than just the annual screening prevalence, and whether
- 363 provision of physical health checks in both physical and mental health services may improve up-take.
- 364 Hypothesis-driven work is required to identify groups of patients most at risk of not receiving CVD
- 365 risk factor screening so that targeted interventions can be developed, with consideration of these
- 366 groups in the planning and implementation of future incentivisation and other improvement
- 367 schemes.

368 References

- 369
- Launders N, Hayes JF, Price G, Osborn DPJ. Clustering of physical health multimorbidity in people
 with severe mental illness: An accumulated prevalence analysis of United Kingdom primary
 care data. *PLoS Medicine* 2022;19(4)
- 2. Firth J, Siddiqi N, Koyanagi A, et al. The Lancet Psychiatry Commission: a blueprint for protecting
 physical health in people with mental illness. *Lancet Psychiatry* 2019;6(8):675-712. doi:
 10.1016/S2215-0366(19)30132-4 [published Online First: 2019/07/22]
- 376 3. Correll CU, Solmi M, Veronese N, et al. Prevalence, incidence and mortality from cardiovascular
 disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis
 of 3,211,768 patients and 113,383,368 controls. *World Psychiatry* 2017;16(2):163-80. doi:
 10.1002/wps.20420 [published Online First: 2017/05/13]
- 4. Lambert AM, Parretti HM, Pearce E, et al. Temporal trends in associations between severe mental illness and risk of cardiovascular disease: A systematic review and meta-analysis. *PLoS Medicine* 2022;19(4):e1003960. doi: 10.1371/journal.pmed.1003960 [published Online First: 2022/04/20]

5. Vancampfort D, Stubbs B, Mitchell AJ, et al. Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis. *World Psychiatry* 2015;14(3):339-47. doi: 10.1002/wps.20252 [published Online First: 2015/09/27]

388 389	6. Launders N, Dotsikas K, Marston L, et al. The impact of comorbid severe mental illness and common chronic physical health conditions on hospitalisation: A systematic review and
390 391	meta-analysis. <i>PLoS One</i> 2022;17(8):e0272498. doi: 10.1371/journal.pone.0272498
392	[published Online First: 2022/08/19] 7. Correll CU, Ng-Mak DS, Stafkey-Mailey D, et al. Cardiometabolic comorbidities, readmission, and
393	costs in schizophrenia and bipolar disorder: a real-world analysis. Annals of general
394	psychiatry 2017;16:9. doi: 10.1186/s12991-017-0133-7 [published Online First: 2017/02/17]
395	8. Kalkhoran S, Thorndike AN, Rigotti NA, et al. Cigarette Smoking and Quitting-Related Factors
396	Among US Adult Health Center Patients with Serious Mental Illness. J Gen Intern Med
397	2019;34(6):986-91. doi: 10.1007/s11606-019-04857-3 [published Online First: 2019/02/21]
398	9. Afzal M, Siddiqi N, Ahmad B, et al. Prevalence of Overweight and Obesity in People With Severe
399	Mental Illness: Systematic Review and Meta-Analysis. Front Endocrinol (Lausanne)
400	2021;12:769309. doi: 10.3389/fendo.2021.769309 [published Online First: 2021/12/14]
401	10. Vancampfort D, Correll CU, Galling B, et al. Diabetes mellitus in people with schizophrenia,
402	bipolar disorder and major depressive disorder: a systematic review and large scale meta-
403	analysis. World Psychiatry 2016;15(2):166-74. doi: 10.1002/wps.20309 [published Online
404	First: 2016/06/07]
405	11. Brauer R, Douglas, I., Smeeth, L. The association between antipsychotic agents and the risk of
406	myocardial infarction: a systematic review. Br J Clin Pharmacol 2011;72(6):871-78. doi:
407	10.1111/j.1365-2125.2011.04043.x
408	12. McCarter R, Rosato M, Thampi A, et al. Physical health disparities and severe mental illness: a
409	longitudinal comparative cohort study using hospital data in Northern Ireland. Eur Psychiatry
410	2023:1-26. doi: 10.1192/j.eurpsy.2023.2441 [published Online First: 20230814]
411	13. Lee SC, DelPozo-Banos M, Lloyd K, et al. Area deprivation, urbanicity, severe mental illness and
412	social drift - A population-based linkage study using routinely collected primary and
413	secondary care data. Schizophr Res 2020;220:130-40. doi: 10.1016/j.schres.2020.03.044
414	[published Online First: 2020/04/07]
415	14. NHS Digital. Quality and Outcomes Framework, 2004-05 2005 [Available from:
416	https://data.england.nhs.uk/dataset/qof-national-quality-outcomes-framework-2004-
417	05/resource/c130ad9e-06b2-47c5-ad42-eeb36b1e8740 accessed 29/09/2022.
418	15. Osborn DP, Baio G, Walters K, et al. Inequalities in the provision of cardiovascular screening to
419	people with severe mental illnesses in primary care: cohort study in the United Kingdom
420	THIN Primary Care Database 2000-2007. <i>Schizophr Res</i> 2011;129(2-3):104-10. doi:
421	10.1016/j.schres.2011.04.003 [published Online First: 2011/05/10]
422	16. Wilson CL, Rhodes KM, Payne RA. Financial incentives improve recognition but not treatment of
423	cardiovascular risk factors in severe mental illness. <i>PLoS One</i> 2017;12(6):e0179392. doi:
424	10.1371/journal.pone.0179392 [published Online First: 2017/06/10]
425	17. Hardoon SL, Khadjesari Z, Nazareth I, et al. Monitoring of alcohol consumption in primary care
426	among adults with bipolar disorder: A cross-sectional and retrospective cohort study. J Affect
427	Disord 2016;198:83-7. doi: 10.1016/j.jad.2016.03.019 [published Online First: 2016/03/26]
428	18. Khadjesari Z, Hardoon SL, Petersen I, et al. Impact of Financial Incentives on Alcohol Consumption
429	Recording in Primary Health Care Among Adults with Schizophrenia and Other Psychoses: A
430	Cross-Sectional and Retrospective Cohort Study. Alcohol Alcohol 2017;52(2):197-205. doi:
430	10.1093/alcalc/agw076 [published Online First: 2017/02/10]
431	19. Matias MA, Jacobs R, Aragon MJ, et al. Assessing the uptake of incentivised physical health
432 433	checks for people with serious mental illness. <i>British Journal of General Practice</i> 2024 doi:
433 434	10.3399/BJGP.2023.0532 [published Online First: 20240208]
434 435	
435	20. Herrett E, Gallagher AM, Bhaskaran K, et al. Data Resource Profile: Clinical Practice Research Datalink (CPRD). <i>International Journal of Epidemiology</i> 2015;44(3):827-36. doi:
430 437	10.1093/ije/dyv098 [published Online First: 2015/06/08]
+J/	10.1033/1Je/ 49/030 [published Online First. 2013/00/06]

438 439 440	 Wolf A, Dedman D, Campbell J, et al. Data resource profile: Clinical Practice Research Datalink (CPRD) Aurum. <i>International Journal of Epidemiology</i> 2019;48(6):1740-40g. doi: 10.1093/ije/dyz034 [published Online First: 2019/03/13]
441	22. NHS Employers. Quality and Outcomes Framework 2016 [Available from:
442	https://webarchive.nationalarchives.gov.uk/ukgwa/20160512105008/http://www.nhsemplo
443	yers.org/your-workforce/primary-care-contacts/general-medical-services/quality-and-
444	outcomes-framework.
445	23. ONS. 2011 Census Varialble and Classification Information: Part 4 - derived variables: Office for
446	National Statistics,, 2014.
447	24. Benchimol EI, Smeeth L, Guttmann A, et al. The REporting of studies Conducted using
448	Observational Routinely-collected health Data (RECORD) statement. PLoS Medicine
449	2015;12(10):e1001885. doi: 10.1371/journal.pmed.1001885 [published Online First:
450	20151006]
451	25. Kontopantelis E, Springate D, Reeves D, et al. Withdrawing performance indicators: retrospective
452	analysis of general practice performance under UK Quality and Outcomes Framework. BMJ
453	2014;348:g330. doi: 10.1136/bmj.g330 [published Online First: 20140127]
454	26. NHS England. Quality and Outcomes Framework guidance for 2023/24 2023 [Available from:
455	https://www.england.nhs.uk/publication/quality-and-outcomes-framework-guidance-for-
456	<u>2023-24/</u> .
457	27. NHS England. The NHS Long Term Plan: NHS England, 2019.
458	28. NHS England. Physical Health Checks for people with Severe Mental Illness 2022 [Available from:
459	https://www.england.nhs.uk/statistics/statistical-work-areas/serious-mental-illness-smi/
460	accessed 30/09/2022.
461	29. Launders N, Hayes JF, Price G, et al. The incidence rate of planned and emergency physical health
462	hospital admissions in people diagnosed with severe mental illness: a cohort study.
463	Pyschological Medicine 2022:1-12. doi: 10.1017/S0033291722002811 [published Online
464	First: 2022/09/08]
465	30. NHS England. Improving the physical health of people living with severe mental illness 2024
466	[Available from: <u>https://www.england.nhs.uk/long-read/improving-the-physical-health-of-</u>
467	people-living-with-severe-mental-illness/.
468	31. Department of Health NI. Quality and Outcomes Framework (QOF) 2022 [Available from:
469	https://www.health-ni.gov.uk/topics/doh-statistics-and-research/quality-outcomes-
470	framework-qof accessed 29/09/2022.
471	32. Welsh Government. General Medical Services Contract Quality and Outcomes Framework
472	Statistics for Wales, 2018-2019, 2019.
473	33. Welsh Government. General Medical Services Contract: Quality and Outcomes Framework
474	Statistics for Wales, 2014-15, 2015.
475	34. Public Health Scotland. Quality and Outcomes Framework: 2014/2015 Achievement at Scotland
476	and NHS Board Level, 2015.
477	35. Department of Health NI. Quality and outcomes framework (QOF) achievement data 2014/15,
478	2015.

Funding statement 480

481 This work was funded by the HDR UK DATAMIND hub, which is funded by the UK Research and 482 Innovation grant MR/W014386/1. NL, JFH, MHI, EB RS, AJ and DPJO acknowledge funding from 483 DATAMIND.

484

485 NL is additionally supported by a Health Data Research UK personal fellowship. This work is affiliated

- 486 to Health Data Research UK (Big Data for Complex Disease- HDR-23012), which is funded by the
- 487 Medical Research Council (UKRI), the National Institute for Health Research, the British Heart
- 488 Foundation, Cancer Research UK, the Economic and Social Research Council (UKRI), the Engineering
- 489 and Physical Sciences Research Council (UKRI), Health and Care Research Wales, Chief Scientist Office
- 490 of the Scottish Government Health and Social Care Directorates, and Health and Social Care Research
- 491 and Development Division (Public Health Agency, Northern Ireland).
- 492 NL & JF are additionally supported by the UK Research and Innovation grant MR/V023373/1. NL, JFH,
- 493 EB & DPJO are supported by the University College London Hospitals NIHR Biomedical Research
- 494 Centre, and NL, JFH & DPJO by the NIHR North Thames Applied Research Collaboration. This funder
- 495 had no role in study design, data collection, data analysis, data interpretation, or writing of the
- 496 report. The views expressed in this article are those of the authors and not necessarily those of the 497 NHS, the NIHR, or the Department of Health and Social Care.
- 498

499 RS is additionally part-funded by: the NIHR Maudsley Biomedical Research Centre at the South

- 500 London and Maudsley NHS Foundation Trust and King's College London; the National Institute for
- 501 Health Research (NIHR) Applied Research Collaboration South London (NIHR ARC South London) at
- 502 King's College Hospital NHS Foundation Trust; the UK Prevention Research Partnership (Violence,
- 503 Health and Society; MR-VO49879/1), an initiative funded by UK Research and Innovation Councils,
- 504 the Department of Health and Social Care (England) and the UK devolved administrations, and
- 505 leading health research charities.
- 506 MHI is additionally supported by the Wellcome Trust (220857/Z/20/Z; 226770/Z/22/Z,
- 507 104036/Z/14/Z; 216767/Z/19/Z) and by a Research Data Scotland Accelerator Award (RAS-24-2.
- 508 EB acknowledges the additional support of: Medical Research Council (G1100583, MR/W020238/1),
- 509 National Institute of Health Research (NIHR200756), Mental Health Research UK - John Grace QC
- 510 Scholarship 2018, Economic Social Research Council's Co-funded doctoral award, The British Medical
- 511 Association's Margaret Temple Fellowship, Medical Research Council New Investigator and Centenary
- 512 Awards (G0901310, G1100583), NIHR BRC at UCLH (Biomedical Research Centre at University College
- 513 London Hospitals NHS Foundation Trust and University College London).

Conflicts of interest 514

- 515 JFH has received consultancy fees from juli Health and Wellcome. He is a co-founder and shareholder
- 516 of juli Health. juli Health has a patent pending. RS declares research support received in the last 3
- 517 years from GSK and Takeda.

Data sharing statement 518

- Data were obtained from a third party and are not publicly available. All data were obtained from 519
- 520 Clinical Practice Research Datalink (CPRD). Data is available from CPRD but is subject to protocol
- approval and ethical review: https://www.cprd.com/research-applications. 521

Acknowledgments 522

- 523 The authors wish to acknowledge the input from the wider collaborators involved in DATAMIND, and
- 524 particularly the input from lived experience advisors.

Author contributions 525

526 NL wrote the protocol, analysed the data and wrote the first draft of the manuscript. JFH and DPJO

had oversight of the data and contributed to the initial study design. CAJ, JFH, AJ, RS, MHI, EB and 527

528 DPJO commented on the study protocol and helped formulate the original research question. All

529 authors provided input on the interpretation of results and commented on the first draft of the

530 manuscript.